e75 peptide long multi-epitope peptide E75-AE36 - mk-677-peptide-sciences an immunogenic peptide derived from the HER2 protein Understanding the E75 Peptide: A Key Player in Cancer Vaccine Development

eating-collagen-peptides The e75 peptide has emerged as a significant component in the ongoing research and development of cancer vaccines, particularly for breast cancer and prostate cancer. This immunogenic peptide, derived from the HER2 protein, holds promise due to its ability to stimulate a targeted immune response against cancer cells that overexpress this protein. The HER2/neu (E75) Peptide is a specific sequence, often referred to as nelipepimut-S, that has been extensively studied for its therapeutic potential.

Expertise and Experience in E75 Peptide Research

The extensive body of research surrounding the e75 peptide underscores the expertise and experience in this field. Numerous studies, including those by GT Clifton, EA Mittendorf, JP Holmes, and EJ Schneble, have contributed to our understanding of its properties and applications. These researchers have explored its use in various formulations, most notably as a peptide vaccine. The consistent citation of these works highlights their foundational role in advancing e75 peptide research.HER2/neu (E75) Peptideis a peptide. This product is made to order. A CoA with HPLC and MS data will be provided with the product. For instance, Mittendorf's work in 2008, cited 131 times, details how the e75 peptide (specifically HER2/neu 369-377) is an immunogenic peptide from the HER2/neu protein that is overexpressed in many breast cancer patients. Similarly, Holmes's research in 2008 investigated the optimal dose and schedule of an HER-2/neu (E75) peptide vaccine, administered with granulocyte–macrophage colony-stimulating factor (GM-CSF).

E75 Peptide as a Targeted Cancer Therapy

The primary mechanism behind the e75 peptide's therapeutic potential lies in its immunogenicity.作者：P Zamani·2020·被引用次数：62—Our study indicated that liposomal formulation containinglong multi-epitope peptide E75-AE36with PADRE could be used as an effective multi-epitope ... It is an immunogenic peptide derived from the HER2 protein, meaning it can trigger an immune response作者：GT Clifton·2016·被引用次数：57—E75 (nelipepimut-S) isan immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte–macrophage colony-stimulating .... Specifically, the e75 peptide is a nine-amino-acid-long polypeptide derived from the HER-2 receptor. It is known to bind to the HLA-A2 molecule, a critical step in activating cytotoxic T lymphocytes (CTLs). These CTLs are crucial for identifying and destroying cancer cells that exhibit the HER2 protein on their surface. This targeted approach makes the e75 peptide a valuable candidate for developing personalized mRNA vaccines and other advanced cancer treatment strategiesFinal report of the phase I/II clinical trial of the E75 ....

Clinical Trials and Applications of the E75 Peptide

The e75 peptide has been evaluated in numerous clinical trials, primarily focusing on its safety and efficacy as a vaccine. Studies have assessed the safety and documented local and systemic toxicity to the peptide vaccine (E75) in patients with node-negative breast cancer.作者：Z You·2021·被引用次数：41—TheE75and GP2 vaccines are the few therapeutic vaccines targeting HER2 currently under clinical research for patients with breast cancer. These trials aim to determine the optimal dose and schedule for its administration. For example, a phase I/II clinical trial of the E75 vaccine, as reported by Mittendorf in 2014, involved patients with HER2-positive breast cancer. Another study revealed that Nelipepimut-S (E75) was a nine-amino-acid peptide extracted from the HER2 protein capable of increasing patient survival rates.

The e75 peptide is recognized as the most frequently studied anti-HER2 vaccination strategy for the treatment of breast cancer. Beyond breast cancer, its application extends to prostate cancer, where it has been investigated as an immunogenic peptide from the HER2/neu protein that is substantially expressedPeptide-Based Vaccine against Breast Cancer. The E75 and GP2 vaccines are noted as among the few therapeutic vaccines currently under clinical research targeting HER2 in breast cancer patients. Furthermore, research is exploring advanced formulations, such as a long multi-epitope peptide E75-AE36 encapsulated in nanoliposomes, which could serve as an effective multi-epitope vaccine.Optimal dose and schedule of an HER-2/neu (E75) peptide ...

The e75 peptide is also available for research purposes, with suppliers offering the HER2/neu (E75) Peptide made to order, providing a CoA with HPLC and MS data to ensure quality and reproducibility in experiments measuring levels or activity. The E75, Her-2/neu (369-377) (E-PP-1077) is one such product used for studying these parameters.

Future Directions and Broader Implications

The ongoing development of peptide-based breast cancer vaccines demonstrates the continued optimism surrounding the e75 peptideLong-term follow-up assessment of a HER-2/neu peptide .... While early trials have shown promise, research is continually refining its application. The development of an effective peptide-based vaccine for COVID-19 and the exploration of personalized mRNA vaccines for cancer treatment signal a broader shift towards precision medicine, where peptides like e75 play a crucial role. The potential for long-term follow-up assessment of a HER-2/neu peptide vaccine in high-risk prostate cancer patients further underscores its versatility作者：EJ Schneble·2014·被引用次数：91—Nelipepimut-S (formerly known as E75) isan immunogenic peptide from the HER2 proteinthat is highly expressed in breast cancer. The NeuVax™ (Galena, OR, .... The e75 peptide represents a significant advancement in the quest for more effective and targeted cancer therapiesThe E75 HER2/neu peptide vaccine.